ough multiple channels, including physicians, pharmacies, hospitals, private companies and distributors in the private sector, and governmental entities and non-governmental organizations in the public and international donor markets, respectively. The company’s Animal Health products are sold and distributed through various channels, depending on each country's legislation for veterinary products. Merial takes into account each country's specific characteristics and sells either to veterinaries, chemists, or via wholesalers. In the case of epizootics, Merial delivers directly to governments. Research and Development Expenditures on research and development amounted to €4,770 million in 2013, comprising €4,087 million in the Pharmaceuticals segment, €518 million in Human Vaccines segment and €165 million in Animal Health segment. Strategy The company executes its strategy along four prongs: growing a global healthcare leader with synergistic platforms; bringing innovative products to market; seizing value enhancing growth opportunities; and adapting its structure for future opportunities and challenges. In May 2014, Sanofi Pasteur, the vaccines division of Sanofi, announced that its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India, has received prequalification status from the World Health Organization (WHO). Significant Events In May 2014, Global Green Inc. announced the 90-day extension of an existing agreement with Merial Ltd., the Animal Health Division of Sanofi. In May 2014, Sanofi signed an agreement with the regional government of Puglia in Italy a deal worth EUR 8.4 million for the expansion of the company's plant in Brindisi to enable the production of antibiotics. Competition The company’s prescription drugs compete in all major markets against patented drugs from major pharmaceutical companies such as: Novo Nordisk and Merck in diabetes; Eli Lilly in diabetes and oncology; Bristol-Myers Squibb in oncology; GlaxoSmithKline in thrombosis and oncology; Novartis in diabetes, multiple sclerosis, thrombosis and oncology; Shire in rare diseases and renal; Pfizer in rare diseases and oncology; Biogen Idec, Teva and Merck Serono in multiple sclerosis; Bayer in multiple sclerosis and thrombosis prevention; Roche in oncology; Johnson & Johnson in oncology and thrombosis prevention; AstraZeneca in cardiovascular diseases and oncology; Boehringer-Ingelheim in diabetes and thrombosis; and Fresenius Medical Care in renal diseases. The company’s CHC business competes with multinational corporations such as Johnson & Johnson, Bayer, Pfizer, Novartis, and GlaxoSmithKline. The company’s generics business competes with multinational corporations such as Teva, Sandoz (a division of Novartis), Mylan and Actavis and local players, especially in emerging markets. In its Human Vaccines business, the company competes primarily with multinational players backed by large healthcare groups, including Merck (outside Europe), GlaxoSmithKline, Pfizer (Wyeth), Novartis and Johnson & Johnson (Crucell). In specific market segments, Sanofi Pasteur competes with mid-size international players (such as CSL of Australia in the influenza market for the Southern Hemisphere). In its Animal Health business, the company competes primarily with international companies like Zoetis, Merck and Elanco in both production and companion animals; with Boehringer Ingelheim in production animals; with Boehringer Ingelheim mainly in the vaccines segment; with Novartis and Bayer for pets, particularly for parasiticides; and with Virbac, Ceva and Vetoquinol, French companies with global presence, for pharmaceuticals and/or vaccines. Significant Events In June 2014, CQDM and Sanofi Canada announced their partnership to support highly innovative research in Quebec and Canada. History The company was founded in 1970. It was formerly known as Sanofi-Aventis and changed its name to Sanofi in 2011.
sanofi-adr (SNY:New York)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
|Bayer AG||€100.10 EUR||-1.31|
|Gilead Sciences Inc||$93.79 USD||+0.80|
|GlaxoSmithKline PLC||1,435 GBp||+10.00|
|Merck & Co Inc||$58.08 USD||-0.50|
|Novo Nordisk A/S||kr257.60 DKK||+0.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-ADR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.